B.Riley Financial Thinks Agenus’ Stock is Going to Recover

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGENResearch Report) today and set a price target of $8.00. The company’s shares closed last Tuesday at $2.35, close to its 52-week low of $2.28.

According to TipRanks.com, Mamtani ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -26.6% and a 23.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Agenus is a Moderate Buy with an average price target of $11.00.

See Insiders’ Hot Stocks on TipRanks >>

Agenus’ market cap is currently $604.3M and has a P/E ratio of -13.52.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Read More on AGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed